Nurix Therapeutics operates at the forefront of targeted protein degradation, leveraging a proprietary DEL-AI platform and advancing three clinical-stage candidates focused on oncology and immunology. Historical performance reveals rapid growth in top-line collaboration revenue but consistent deepening net losses driven by heavy investment in R&D and platform expansion. The company’s extensive partnerships with Gilead, Sanofi, and Pfizer provide important non-dilutive funding and pipeline validation, yet clinical and regulatory risks remain significant. Upcoming clinical trial progress and potential marketing approvals will be key milestones to monitor amid uncertain timing for profitability.